The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines

Proteomics

Volumn 12, Issue 13, 2012, Pages 2115-2126

  O'Connell, Kathleen ^a   Prencipe, Maria ^b   O'Neill, Amanda ^b   Corcoran, Claire ^c   Rani, Sweta ^c   Henry, Michael ^a   Dowling, Paul ^a   Meleady, Paula ^a   O'Driscoll, Lorraine ^c   Watson, William ^c   O'Connor, Robert ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cancer; Cell biology; Docetaxel; Prostate; Resistant

Indexed keywords

DOCETAXEL;

ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEOMICS;

CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CYTOSKELETAL PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MASS SPECTROMETRY; PROSTATE; PROSTATIC NEOPLASMS; PROTEINS; PROTEOMICS; RADIATION-SENSITIZING AGENTS; RECEPTORS, ANDROGEN; TAXOIDS;

EID: 84864021456     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100489     Document Type: Article

References (71)

1. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J. Clin. 2011, 61, 133-134.
2. Siegel, R., Ward, E., Brawley, O., Jemal, A., Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61, 212-236.
3. Hayat, M. J., Howlader, N., Reichman, M. E., Edwards, B. K., Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007, 12, 20-37.
4. Denmeade, S. R., Lin, X. S., Isaacs, J. T., Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996, 28, 251-265.
5. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G. et al., Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 1995, 55, 3068-3072.
6. Tannock, I. F., de Wit, R., Berry, W. R., Horti, J. et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351, 1502-1512.
7. Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr. et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351, 1513-1520.
8. Urakami, S., Igawa, M., Kikuno, N., Yoshino, T. et al., Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J. Urol. 2002, 168, 2444-2450.
9. Berthold, D. R., Pond, G. R., Soban, F., de Wit, R. et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 2008, 26, 242-245.
10. Baker, S. D., Sparreboom, A., Verweij, J., Clinical pharmacokinetics of docetaxel: recent developments. Clin. Pharmacokinet 2006, 45, 235-252.
11. Bruno, R., Hille, D., Riva, A., Vivier, N. et al., Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J. Clin. Oncol. 1998, 16, 187-196.
12. Di Lorenzo, G., Buonerba, C., Faiella, A., Rescigno, P. et al., Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2011, 107, 234-239.
13. Raghavan, D., Koczwara, B., Javle, M., Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur. J. Cancer 1997, 33, 566-574.
14. Ploussard, G., Terry, S., Maille, P., Allory, Y. et al., Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 70, 9253-9264.
15. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I. et al., Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999, 59, 4291-4296.
16. Feldman, B. J., Feldman, D., The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1, 34-45.
17. McEleny, K., Coffey, R., Morrissey, C., Williamson, K. et al., An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to fas and TNFalpha mediated apoptosis. Prostate 2004, 59, 419-425.
18. Patterson, S. G., Wei, S., Chen, X., Sallman, D. A. et al., Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006, 25, 6113-6122.
19. Zhong, B., Sallman, D. A., Gilvary, D. L., Pernazza, D. et al., Induction of clusterin by AKT-role in cytoprotection against docetaxel in prostate tumor cells. Mol. Cancer Ther. 9, 1831-1841.
20. Gibbons, N. B., Watson, R. W., Coffey, R. N., Brady, H. P. et al., Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 2000, 45, 58-65.
21. Li, X. H., Li, C., Xiao, Z. Q., Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer. J. Proteomics 74, 2642-2649.
22. Fredolini, C., Liotta, L. A., Petricoin, E. F., Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy. Crit. Rev. Clin. Lab Sci. 2010, 47, 125-138.
23. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M. et al., Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991, 324, 1156-1161.
24. Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
25. Sardana, G., Jung, K., Stephan, C., Diamandis, E. P., Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 2008, 7, 3329-3338.
26. M'Koma, A. E., Blum, D. L., Norris, J. L., Koyama, T. et al., Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem. Biophys. Res. Commun. 2007, 353, 829-834.
27. Glen, A., Gan, C. S., Hamdy, F. C., Eaton, C. L. et al., iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J. Proteome Res. 2008, 7, 897-907.
28. Zhao, L., Lee, B. Y., Brown, D. A., Molloy, M. P. et al., Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res. 2009, 69, 7696-7703.
29. O'Neill, A. J., Prencipe, M., Dowling, C., Fan, Y. et al., Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol. Cancer 10, 126. doi: 10.1186/1476-4598-10-126
30. Duan, X., Young, R., Straubinger, R. M., Page, B. et al., A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J. Proteome Res. 2009, 8, 2838-2850.
31. Nikitin, A., Egorov, S., Daraselia, N., Mazo, I., Pathway studio-the analysis and navigation of molecular networks. Bioinformatics 2003, 19, 2155-2157.
32. Keller, B. O., Sui, J., Young, A. B., Whittal, R. M., Interferences and contaminants encountered in modern mass spectrometry. Anal. Chim. Acta 2008, 627, 71-81.
33. van Bokhoven, A., Varella-Garcia, M., Korch, C., Johannes, W. U. et al., Molecular characterization of human prostate carcinoma cell lines. Prostate 2003, 57, 205-225.
34. Dozmorov, M. G., Hurst, R. E., Culkin, D. J., Kropp, B. P. et al., Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate 2009, 69, 1077-1090.
35. Uchida, K., Chaudhary, L. R., Sugimura, Y., Adkisson, H. D. et al., Proprotein convertases regulate activity of prostate epithelial cell differentiation markers and are modulated in human prostate cancer cells. J. Cell Biochem. 2003, 88, 394-399.
36. Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E. et al., Towards a knowledge-based human protein atlas. Nat. Biotechnol. 28, 1248-1250.
37. Tepper, C. G., Boucher, D. L., Ryan, P. E., Ma, A. H. et al., Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 2002, 62, 6606-6614.
38. Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E. et al., Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350.
39. Thiery, J. P., Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442-454.
40. Kiemer, A. K., Takeuchi, K., Quinlan, M. P., Identification of genes involved in epithelial-mesenchymal transition and tumor progression. Oncogene 2001, 20, 6679-6688.
41. Savagner, P., The epithelial-mesenchymal transition (EMT) phenomenon. Ann. Oncol. 2010, 21(Suppl 7), vii89-vii92.
42. Iseri, O. D., Kars, M. D., Gunduz, U., Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern. Mol. Biol. Rep. 2011, 39, 3505-3516.
43. Kajiyama, H., Shibata, K., Terauchi, M., Yamashita, M. et al., Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 2007, 31, 277-283.
44. Hiscox, S., Jiang, W. G., Obermeier, K., Taylor, K. et al., Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int. J. Cancer 2006, 118, 290-301.
45. Huber, M. A., Azoitei, N., Baumann, B., Grunert, S. et al., NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest 2004, 114, 569-581.
46. Lindquist, S., Craig, E. A., The heat-shock proteins. Annu. Rev. Genet 1988, 22, 631-677.
47. Kampinga, H. H., Chaperones in preventing protein denaturation in living cells and protecting against cellular stress. Handb. Exp. Pharmacol. 2006, 172, 1-42.
48. Bagatell, R., Whitesell, L., Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. 2004, 3, 1021-1030.
49. Isaacs, J. S., Xu, W., Neckers, L., Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3, 213-217.
50. Kim, Y., Lillo, A. M., Steiniger, S. C., Liu, Y. et al., Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry 2006, 45, 9434-9444.
51. Whitesell, L., Lindquist, S. L., HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772.
52. Neckers, L., Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8, S55-S61.
53. Solit, D. B., Zheng, F. F., Drobnjak, M., Munster, P. N. et al., 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 2002, 8, 986-993.
54. O'Malley, K. J., Langmann, G., Ai, J., Ramos-Garcia, R. et al., Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate 2011. doi: 10.1002/pros.22458
55. Pootrakul, L., Datar, R. H., Shi, S. R., Cai, J. et al., Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin. Cancer Res. 2006, 12, 5987-5993.
56. Daneshmand, S., Quek, M. L., Lin, E., Lee, C. et al., Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum. Pathol. 2007, 38, 1547-1552.
57. Tan, S. S., Ahmad, I., Bennett, H. L., Singh, L. et al., GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J. Pathol. 223, 81-87.
58. Ravagnan, L., Gurbuxani, S., Susin, S. A., Maisse, C. et al., Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat. Cell Biol. 2001, 3, 839-843.
59. Gabai, V. L., Budagova, K. R., Sherman, M. Y., Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 2005, 24, 3328-3338.
60. Ren, A., Yan, G., You, B., Sun, J., Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res. 2008, 68, 2266-2274.
61. Schmitt, E., Maingret, L., Puig, P. E., Rerole, A. L. et al., Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006, 66, 4191-4197.
62. Zhao, Z. G., Shen, W. L., Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901. World J. Gastroenterol. 2005, 11, 73-78.
63. Goetz, M. P., Toft, D., Reid, J., Ames, M. et al., Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 1078-1087.
64. van der Kwast, T. H., Schalken, J., Ruizeveld de Winter, J. A., van Vroonhoven, C. C. et al., Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer 1991, 48, 189-193.
65. Alimirah, F., Chen, J., Basrawala, Z., Xin, H. et al., DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett. 2006, 580, 2294-2300.
66. Frigo, D. E., McDonnell, D. P., Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol. Cancer Ther. 2008, 7, 659-669.
67. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A. et al., Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992, 31, 2393-2399.
68. Loy, C. J., Sim, K. S., Yong, E. L., Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc. Natl. Acad. Sci. USA 2003, 100, 4562-4567.
69. Leav, I., Plescia, J., Goel, H. L., Li, J. et al., Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am. J. Pathol. 176, 393-401.
70. Zhu, M. L., Horbinski, C. M., Garzotto, M., Qian, D. Z. et al., Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992-8002.
71. Compagno, D., Merle, C., Morin, A., Gilbert, C. et al., SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS One 2007, 2, e1006.